NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to
enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in
diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide
neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in
glaucoma. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into
one eye, and will be carefully followed to evaluate safety and efficacy.